LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1043

Search options

  1. Book: Hepatitis C Virus HIV co-infection

    Chung, Raymond T.

    (The journal of infectious diseases ; 207, Suppl. 1)

    2013  

    Title variant Hepatitis C Virus-HIV co-infection
    Author's details ed.: Raymond T. Chung
    Series title The journal of infectious diseases ; 207, Suppl. 1
    Collection
    Language English
    Size S44 S. : graph. Darst.
    Publisher Oxford Univ. Press
    Publishing place Cary, NC
    Publishing country United States
    Document type Book
    HBZ-ID HT017573253
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Uh II Zs 50 -207,Suppl.1- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.

    Przybyszewski, Eric M / Chung, Raymond T

    The Journal of infectious diseases

    2023  Volume 228, Issue Suppl 3, Page(s) S226–S231

    Abstract: Infection with chronic hepatitis C virus (HCV) is an important risk factor for hepatocellular carcinoma (HCC). Direct-acting antiviral therapy has transformed care for patients with HCV and reduces the risk of HCC. Despite HCV cure, a residual HCC risk ... ...

    Abstract Infection with chronic hepatitis C virus (HCV) is an important risk factor for hepatocellular carcinoma (HCC). Direct-acting antiviral therapy has transformed care for patients with HCV and reduces the risk of HCC. Despite HCV cure, a residual HCC risk remains in patients with advanced fibrosis and cirrhosis, with multiple mechanisms underlying subsequent hepatocarcinogenesis. Transcriptomic and proteomic signatures demonstrate the capacity for HCC risk stratification, and chemoprevention strategies are emerging. For now, pending more precise stratification, HCC surveillance of patients with cured HCV and advanced fibrosis or cirrhosis should continue.
    MeSH term(s) Humans ; Hepacivirus/genetics ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/drug therapy ; Antiviral Agents/therapeutic use ; Carcinoma, Hepatocellular/epidemiology ; Carcinoma, Hepatocellular/etiology ; Carcinoma, Hepatocellular/prevention & control ; Proteomics ; Liver Neoplasms/epidemiology ; Liver Neoplasms/etiology ; Liver Neoplasms/prevention & control ; Hepatitis C ; Liver Cirrhosis ; Carcinogenesis
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2023-09-13
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiac447
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.50: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 445: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Systematic review: efficacy of therapies for cholestatic pruritus.

    Ebhohon, Ebehiwele / Chung, Raymond T

    Therapeutic advances in gastroenterology

    2023  Volume 16, Page(s) 17562848231172829

    Abstract: Background: Pruritus is a symptom of several cholestatic liver diseases (CLDs) that can impair health-related quality of life (HRQoL). Despite evidence-based guideline therapy, managing cholestatic pruritus (CP) remains challenging, thus making the need ...

    Abstract Background: Pruritus is a symptom of several cholestatic liver diseases (CLDs) that can impair health-related quality of life (HRQoL). Despite evidence-based guideline therapy, managing cholestatic pruritus (CP) remains challenging, thus making the need for newer, more effective therapeutic agents more evident.
    Objective: Our study evaluated the efficacy of existing CP therapies.
    Design: Systematic review.
    Data sources: From inception until March 2023, we conducted a comprehensive search of MEDLINE, Cochrane, EMBASE, Scopus, ClinicalTrial.gov, and other sources, including pharmaceutical webpages and conference proceedings published in English that reported on CP interventions.
    Methods: Two reviewers independently conducted screening and full-text review of articles with extraction conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The methodological quality of studies included in our qualitative synthesis was assessed by using the Cochrane ROBINS-I and ROBINS-II tools for interventional studies and the National Heart, Lung, and Blood Institute Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. The primary outcome assessed in our systematic review was the severity of CP after therapy.
    Results: Of 3293 screened articles, 92 studies were eligible for inclusion in the qualitative synthesis. Some patients' HRQoL improved with evidence-based standard therapy. Others, particularly those with severe and refractory CP, often required conversion to or addition of experimental noninvasive (e.g., ondansetron) or extracorporeal liver support to alleviate CP. In addition, studies investigating a newer class drug, the ileal bile acid transporter inhibitor (IBATi), demonstrate its effectiveness in reducing serum bile acid and alleviating CP with sustained improvement noted in patients with the inherited childhood cholestatic disorders - progressive familial intrahepatic cholestasis and Alagille syndrome.
    Conclusion: Our findings consolidate data on the efficacy of guideline-based approaches and newer therapies for CP. While the initial findings are promising, additional clinical trials will be needed to determine the full extent of IBATi's efficacy and potential use in treating other common CLDs. These results provide a foundation for future research and highlight the need for continued investigation into the management and treatment of CLDs.
    Language English
    Publishing date 2023-05-25
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2440710-0
    ISSN 1756-2848 ; 1756-283X
    ISSN (online) 1756-2848
    ISSN 1756-283X
    DOI 10.1177/17562848231172829
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: HBV reactivation and clinical resolution in an isolated anti-HBc-positive patient during immune checkpoint inhibition.

    Baumert, Lukas S / Shih, Angela R / Chung, Raymond T

    Med (New York, N.Y.)

    2024  Volume 5, Issue 2, Page(s) 126–131.e1

    Abstract: ... treatment.: Funding: R.T.C. was supported by the MGH Research Scholars Program. ...

    Abstract Background: Immune checkpoint inhibitor (ICI)-related liver injury is a growing concern as ICIs are increasingly used in cancer treatment regimens. Interestingly, ICIs have exhibited antiviral effects among patients with chronic hepatitis B virus (HBV). However, the underlying mechanisms remain unclear, and clinical data on patients with previous HBV infection/exposure and isolated anti-HBV core antibodies (IAHBcs) are lacking.
    Methods: We report a case illustrating the dual effects of ICIs in a patient experiencing panlobular hepatitis and concurrent HBV reactivation.
    Findings: A 68-year-old male patient positive for IAHBcs was admitted with panlobular hepatitis and HBV reactivation after receiving systemic chemotherapy (several months before admission) and ICI treatment (4 weeks before admission) subsequent to metastatic primary lung cancer (NSCLC stage IV). This was followed by a rapid and significant decrease of HBV DNA viral load before and during antiviral treatment.
    Conclusions: This unique case sheds light on the dynamics of ICI therapy in IAHBc-positive patients experiencing HBV reactivation during chemotherapy and underscores the dual impact of ICIs. Moreover, it emphasizes the need for assessment of HBV serology and prophylaxis in IAHBc-positive patients undergoing chemotherapy and ICI treatment.
    Funding: R.T.C. was supported by the MGH Research Scholars Program.
    MeSH term(s) Male ; Humans ; Aged ; Hepatitis B virus/physiology ; Immune Checkpoint Inhibitors/adverse effects ; Hepatitis B, Chronic/complications ; Hepatitis B, Chronic/drug therapy ; Hepatitis B Surface Antigens/pharmacology ; Hepatitis B Surface Antigens/therapeutic use ; Neoplasms ; Antiviral Agents/therapeutic use ; Antiviral Agents/adverse effects
    Chemical Substances Immune Checkpoint Inhibitors ; Hepatitis B Surface Antigens ; Antiviral Agents
    Language English
    Publishing date 2024-02-10
    Publishing country United States
    Document type Case Reports ; Journal Article
    ISSN 2666-6340
    ISSN (online) 2666-6340
    DOI 10.1016/j.medj.2024.01.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Reply.

    Bloom, Patricia P / Chung, Raymond T

    Hepatology (Baltimore, Md.)

    2020  Volume 73, Issue 2, Page(s) 875–876

    Keywords covid19
    Language English
    Publishing date 2020-07-21
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 604603-4
    ISSN 1527-3350 ; 0270-9139
    ISSN (online) 1527-3350
    ISSN 0270-9139
    DOI 10.1002/hep.31510
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1660: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Management of liver disease and portal hypertension in common variable immunodeficiency (CVID).

    Baumert, Lukas S / Shih, Angela / Chung, Raymond T

    JHEP reports : innovation in hepatology

    2023  Volume 5, Issue 11, Page(s) 100882

    Abstract: Patients with common variable immunodeficiency (CVID) frequently develop liver disease and associated complications, which represent an increasingly prevalent unmet medical need. The main hepatic manifestation of CVID is nodular regenerative hyperplasia ( ...

    Abstract Patients with common variable immunodeficiency (CVID) frequently develop liver disease and associated complications, which represent an increasingly prevalent unmet medical need. The main hepatic manifestation of CVID is nodular regenerative hyperplasia (NRH), resulting in non-cirrhotic portal hypertension (NCPH). Liver disease is often underdiagnosed, leading to poor outcomes and decreased survival. The increasing numbers of patients with CVID who are diagnosed late with progressive liver disease underscores the importance of appropriate clinical management and treatment of liver complications. At the same time, specific guidelines for the clinical management of CVID-related liver disease are still lacking. Here, we review the epidemiology of CVID-related liver disease, reveal new insights into NRH and NCPH biology and highlight recently uncovered opportunities for NCPH diagnostics in CVID. Finally, we focus on current management of liver disease, portal hypertension and its complications - the key challenge in patients with CVID. Specifically, we review recent data regarding the role of transjugular intrahepatic portosystemic shunt and liver transplantation in clinical management. The role for anticoagulants and immunosuppressants targeting the pathogenesis of NRH will also be discussed. We propose an updated algorithm for the diagnostic work-up and treatment of NCPH in CVID. Finally, we consider future needs and therapeutic opportunities for CVID-related liver disease.
    Language English
    Publishing date 2023-08-13
    Publishing country Netherlands
    Document type Journal Article ; Review
    ISSN 2589-5559
    ISSN (online) 2589-5559
    DOI 10.1016/j.jhepr.2023.100882
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: A New Model to Assess Hepatitis B Virus Covalently Closed Circular DNA: A Window Into a Previously Hidden Space?

    Xu, Min / Lin, Wenyu / Chung, Raymond T

    Cellular and molecular gastroenterology and hepatology

    2022  Volume 13, Issue 4, Page(s) 1255–1256

    MeSH term(s) DNA, Circular/genetics ; DNA, Viral/genetics ; Hepatitis B virus/genetics
    Chemical Substances DNA, Circular ; DNA, Viral
    Language English
    Publishing date 2022-01-25
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2819778-1
    ISSN 2352-345X ; 2352-345X
    ISSN (online) 2352-345X
    ISSN 2352-345X
    DOI 10.1016/j.jcmgh.2022.01.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Shortening treatment with direct-acting antivirals in HCV-positive organ transplantation.

    Holmes, Jacinta A / Chung, Raymond T

    The lancet. Gastroenterology & hepatology

    2020  Volume 5, Issue 7, Page(s) 626–627

    MeSH term(s) Antiviral Agents ; Ezetimibe ; Hepatitis C ; Hepatitis C, Chronic ; Humans ; Organ Transplantation
    Chemical Substances Antiviral Agents ; Ezetimibe (EOR26LQQ24)
    Language English
    Publishing date 2020-06-18
    Publishing country Netherlands
    Document type Journal Article ; Comment
    ISSN 2468-1253
    ISSN (online) 2468-1253
    DOI 10.1016/S2468-1253(20)30154-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Implementation of a controlled human infection model for evaluation of HCV vaccine candidates.

    Barnes, Eleanor / Cooke, Graham S / Lauer, Georg M / Chung, Raymond T

    Hepatology (Baltimore, Md.)

    2023  Volume 77, Issue 5, Page(s) 1757–1772

    Abstract: ... Promising new vaccine technologies that generate high magnitude antiviral T and B cell immune responses and ...

    Abstract Hepatitis C virus (HCV) remains a major global health concern. Directly acting antiviral (DAA) drugs have transformed the treatment of HCV. However, it has become clear that, without an effective HCV vaccine, it will not be possible to meet the World Health Organization targets of HCV viral elimination. Promising new vaccine technologies that generate high magnitude antiviral T and B cell immune responses and significant new funding have recently become available, stimulating the HCV vaccine pipeline. In the absence of an immune competent animal model for HCV, the major block in evaluating new HCV vaccine candidates will be the assessment of vaccine efficacy in humans. The development of a controlled human infection model (CHIM) for HCV could overcome this block, enabling the head-to-head assessment of vaccine candidates. The availability of highly effective DAA means that a CHIM for HCV is possible for the first time. In this review, we highlight the challenges and issues with currently available strategies to assess HCV vaccine efficacy including HCV "at-risk" cohorts and animal models. We describe the development of CHIM in other infections that are increasingly utilized by trialists and explore the ethical and safety concerns specific for an HCV CHIM. Finally, we propose an HCV CHIM study design including the selection of volunteers, the development of an infectious inoculum, the evaluation of host immune and viral parameters, and the definition of study end points for use in an HCV CHIM. Importantly, the study design (including number of volunteers required, cost, duration of study, and risk to volunteers) varies significantly depending on the proposed mechanism of action (sterilizing/rapid viral clearance vs. delayed viral clearance) of the vaccine under evaluation. We conclude that an HCV CHIM is now realistic, that safety and ethical concerns can be addressed with the right study design, and that, without an HCV CHIM, it is difficult to envisage how the development of an HCV vaccine will be possible.
    MeSH term(s) Animals ; Humans ; Antiviral Agents/pharmacology ; Hepatitis C ; Hepacivirus
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2023-04-17
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 604603-4
    ISSN 1527-3350 ; 0270-9139
    ISSN (online) 1527-3350
    ISSN 0270-9139
    DOI 10.1002/hep.32632
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1660: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: New approaches in viraemic organ transplantation and antiviral therapies.

    Holmes, Jacinta A / Chung, Raymond T

    Nature reviews. Gastroenterology & hepatology

    2020  Volume 17, Issue 2, Page(s) 78–79

    MeSH term(s) Antiviral Agents/therapeutic use ; Carbamates/therapeutic use ; Carcinoma, Hepatocellular/epidemiology ; Guanine/analogs & derivatives ; Guanine/therapeutic use ; Hepatitis B, Chronic/drug therapy ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/prevention & control ; Heterocyclic Compounds, 4 or More Rings/therapeutic use ; Humans ; Liver Neoplasms/epidemiology ; Liver Transplantation/methods ; Macrocyclic Compounds/therapeutic use ; Salvage Therapy ; Sofosbuvir/therapeutic use ; Sulfonamides/therapeutic use ; Tenofovir/therapeutic use ; Transplants/virology
    Chemical Substances Antiviral Agents ; Carbamates ; Heterocyclic Compounds, 4 or More Rings ; Macrocyclic Compounds ; Sulfonamides ; voxilaprevir (0570F37359) ; entecavir (5968Y6H45M) ; Guanine (5Z93L87A1R) ; Tenofovir (99YXE507IL) ; velpatasvir (KCU0C7RS7Z) ; Sofosbuvir (WJ6CA3ZU8B)
    Language English
    Publishing date 2020-01-27
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2493722-8
    ISSN 1759-5053 ; 1759-5045
    ISSN (online) 1759-5053
    ISSN 1759-5045
    DOI 10.1038/s41575-019-0257-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6020: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 97: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top